.Pharmacolibrary.Drugs.ATC.J.J05AH01

Information

Zanamivir is a neuraminidase inhibitor antiviral drug used to treat and prevent influenza A and B. It is administered by inhalation and is currently approved for clinical use in many countries.

Pharmacokinetics

Reported pharmacokinetic parameters in healthy adult volunteers after inhaled administration.

References

1. Zuo, P, et al., & Hossain, M (2020). Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza. Clinical and translational science 13(1) 157–168. DOI:10.1111/cts.12697 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31664778

2. Yoshihara, K, et al., & Kubo, Y (2013). Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection. Drug metabolism and pharmacokinetics 28(5) 416–426. DOI:10.2133/dmpk.dmpk-12-rg-115 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23574886

3. Peng, AW, et al., & Moore, KH (2000). A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. Journal of clinical pharmacology 40(3) 242–249. DOI:10.1177/00912700022008900 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10709152

Revisions

• 06/2025 initial generated model